Sorrento Therapeutics, Inc (SRNE)

Etorro trading 970x250
Sorrento Therapeutics, Inc (SRNE) Logo

About Sorrento Therapeutics, Inc

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California. Address: 4955 Directors Place, San Diego, CA, United States, 92121

Sorrento Therapeutics, Inc News and around…

Latest news about Sorrento Therapeutics, Inc (SRNE) common stock and company :

2 Moonshot Biotechs with 10x Potential
22 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This strategy identified LGVN stock a month ago, and now its price has skyrocketed. Here are two more biotechs that could do the same. The post 2 Moonshot Biotechs with 10x Potential appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market
22 Nov, 2021 Yahoo! Finance

SAN DIEGO and MEXICO CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with a leading local distributor for the sale and distribution of up to 5 million COVI-STIX™ tests for the Mexican market. Since its commercial launch in July, the COVI-STIX COVID-19 Virus Rapid Antigen Detection Test has been well received for its ease of use and rapid generation of results. In a

Market Briefing For Wednesday, Nov. 17 - The EV Edition
17 Nov, 2021 FinancialContent

Raising expectations is exactly what Wall Street needed, to deny any sort of 'double-top' possibility for S&P. Perhaps that's why Goldman Sachs chose today to increase their target to 5100.

With Progress on Multiple Fronts, Sorrento Stock Is a Great Buy: Analyst
16 Nov, 2021 Yahoo! Finance

Sorrento Therapeutics (SRNE) has plans to shortly advance its Bruton’s tyrosine kinase (Btk) inhibitor abivertinib into pivotal testing for the treatment of hospitalized COVID-19-infected patients, yet abivertinib has recently been making waves as a possible therapy for an entirely different disease. Last week, the peer-reviewed journal Clinical Cancer Research published the results from a pivotal study based in China in which abivertinib was tested on 227 heavily pretreated NSCLC (non-small cel

Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City
12 Nov, 2021 Yahoo! Finance

SAN DIEGO and MEXICO CITY, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento’s COVI-STIX COVID-19 Virus Rapid Antigen Detection Test (“COVI-STIX”) will be used for screening all attendees of the upcoming 59th World Boxing Council Annual Convention in Mexico City, Mexico (November 14th through November 18th). The pandemic brought the world to a standstill and while most sports froze, boxing r

Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research
12 Nov, 2021 Yahoo! Finance

Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR and Bruton’s tyrosine kinase (BTK) in advanced NSCLC patients resistant to first-line EGFR kinase inhibitor therapies.In this pivotal study conducted in China, 227 heavily pretreated NSCLC patients were enrolled and among 209 response evaluable patients, confirmed overall response rate (ORR) was 52.2%. Disease control rate (DCR) was 88.0%. The median duration o

Interesting SRNE Put And Call Options For December 31st
11 Nov, 2021 FinancialContent

Investors in Sorrento Therapeutics Inc (SRNE) saw new options begin trading today, for the December 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRNE options chain for the new December 31st contracts and identified one put and one call contract of particular interest.

DYAI: Two New Deals & A Pharma in the Wings
11 Nov, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:DYAI NASDAQ:SRNE READ THE FULL DYAI RESEARCH REPORT Third Quarter 2021 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) released third quarter 2021 operational and financial results on November 10, 2021 and concurrently filed its Form 10-Q with the SEC. Following the release, an investor conference call was held. Highlights for the year

Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
09 Nov, 2021 FinancialContent
Market Briefing For Tuesday, Nov. 9
09 Nov, 2021 FinancialContent

Optimizing portfolio strategies in this market, is fairly straight-forward, even if it doesn't fit catch-phrase descriptions of overbought vs oversold or valuations in an extended or undervalued way. The reason is because it's all those.

Sorrento Awarded California Competes Tax Credit
07 Nov, 2021 Yahoo! Finance

SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”) between Sorrento and the California Governor’s Office of Business and Economic Development (“GO-Biz”). Pursuant to the Agreement, Sorrento has been awarded, subject to the satisfaction of certain milestones specified in the Agreement, an income ta

First Week of December 17th Options Trading For Sorrento Therapeutics (SRNE)
05 Nov, 2021 FinancialContent

Investors in Sorrento Therapeutics Inc (SRNE) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRNE options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

December 23rd Options Now Available For Sorrento Therapeutics (SRNE)
04 Nov, 2021 FinancialContent

Investors in Sorrento Therapeutics Inc (SRNE) saw new options become available today, for the December 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRNE options chain for the new December 23rd contracts and identified one put and one call contract of particular interest.

Market Briefing For Thursday, Nov. 4
04 Nov, 2021 FinancialContent

Offsetting influences are factors which influence the superficially neutral policies of the Fed. By maintaining 'emergency' near-zero rates after the 'emergency', it's soothing to markets, but actually increases certain concerns down-the-line.

Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil
03 Nov, 2021 Yahoo! Finance

COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil.Commercialization in progress with distribution agreement locally established and initial purchase orders pending processing.COVISTIX test is an ideal diagnostic tool for potential deployment in surveillance and disease tracking programs. SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) to

Best Biotech Stocks To Buy Now? 5 To Check Out In November 2021
01 Nov, 2021 FinancialContent
Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer
01 Nov, 2021 Yahoo! Finance

Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharma.China National Medical Products Administration (NMPA) accepted the filing of socazolimab for the cervical cancer indication. SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma, HKEX: 950) has subm

Will Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? What You Should Know
29 Oct, 2021 Yahoo! Finance

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Market Briefing For Thursday, Oct. 28
28 Oct, 2021 FinancialContent

Dangers continue to lurk for the S&P and over-blown mega-caps.But maybe mediocre growth would make politicians more willing to support the big spending bills...

UPDATE  – Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients
27 Oct, 2021 Yahoo! Finance

Abivertinib is an oral capsule (100 mg QD or two 50-mg capsules a day) that potentially reduces cytokine storm associated with acute respiratory distress syndrome (ARDS) in severe hospitalized COVID-19 patients.Preliminary results from two completed Phase 2 studies: US study (N=96) and Brazil study (N=400) have identified an At-Risk COVID-19 Patient Population - Hospitalized COVID patients receiving oxygen support by non-invasive ventilation or high flow oxygen - which can potentially benefit fr

Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients
27 Oct, 2021 Yahoo! Finance

Abivertinib is an oral capsule (100 mg QD or two 50-mg capsules a day) that potentially reduces cytokine storm associated with acute respiratory distress syndrome (ARDS) in severe hospitalized COVID-19 patients.Preliminary results from two completed Phase 2 studies: US study (N=96) and Brazil study (N=400) have identified an At-Risk COVID-19 Patient Population - Hospitalized COVID patients receiving oxygen support by non-invasive ventilation or high flow oxygen - which can potentially benefit fr

Sorrento: Covid-19 Tests Could Generate Significant Revenue, Says Analyst
26 Oct, 2021 Yahoo! Finance

Shares of Sorrento Therapeutics (SRNE) have been on the backfoot for most of the year, retreating by 63% since the February peaks. Throughout the downturn, however, one Street analyst has been backing the biotech; H.C. Wainwright’s Ram Selvaraju thinks the stock is poised to claw back those gains and some. The analyst reiterated a Buy rating on SRNE, along with a $26 price target. If correct, investors could be lining their pockets with a huge 286% gain. (To watch Selvaraju’s track record, click

December 3rd Options Now Available For Sorrento Therapeutics (SRNE)
21 Oct, 2021 FinancialContent

Investors in Sorrento Therapeutics Inc (SRNE) saw new options begin trading today, for the December 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRNE options chain for the new December 3rd contracts and identified one put and one call contract of particular interest.

Market Briefing For Thursday, Oct. 21
21 Oct, 2021 FinancialContent

Margin 'compression' is a traditional concern about stock prices, especially in big-cap issues, which depend on ongoing operations more than technology, as is often priced based on forthcoming rather than existing revenues.

Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device
20 Oct, 2021 Yahoo! Finance

COVISTIX has received CE mark and marketing authorization from FAMHP (Federal Agency for Medicines and Health Products) that enables Sorrento to sell this device in all territories that accept the Qarad EC-Rep (Belgium) CE Mark for commercialization.Distribution contracts are being negotiated. SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received an official CE Mark for COVISTIX and a Registration Number: BE/CA01/

Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
20 Oct, 2021 FinancialContent
Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors
13 Oct, 2021 Yahoo! Finance

Anti-TROP-2 ADC with a drug payload SN38 (a DNA polymerase inhibitor) (ESG-401) has received FDA authorization to begin clinical trials in the US.ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma. SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") previously announced that its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary

FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain
13 Oct, 2021 Yahoo! Finance

Phase 2 trial of resiniferatoxin (RTX) to proceed following clearance from FDA.The decision is supported by the Phase 1 data confirming RTX safety for epidural administration without dose limiting toxicity at any doses tested up to 30 ug.Safety and initial pain relief observed in patients with advanced cancer support RTX as a good candidate for long-term control of refractory cancer pain in a broad spectrum of patients.RTX is a drug that very specifically targets cells carrying the TRPV1 “heat a

Market Briefing For Wednesday, Oct.13
13 Oct, 2021 FinancialContent

A complex battle has been outlined on both sides of S&P 4400. So, having forecast the rebounds to that area, we expected no defining structure, quickly answering questions about whether there was more correction ahead.

SRNE November 26th Options Begin Trading
07 Oct, 2021 FinancialContent

Investors in Sorrento Therapeutics Inc (SRNE) saw new options begin trading today, for the November 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SRNE options chain for the new November 26th contracts and identified one put and one call contract of particular interest.

Sorrento Therapeutics, Inc (SRNE) is a NASDAQ Common Stock listed in , ,

970x250